Abcam, ab263169, Human DGKD knockout HeLa cell lysate

Size: 1Kit
DGKD KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon14.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon14.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-DGKD, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DGKD also known as Diacylglycerol kinase delta plays an essential role in lipid signaling by converting diacylglycerol (DAG) into phosphatidic acid (PA). This enzymatic activity impacts cellular processes such as growth and differentiation. The DGKD protein has a molecular mass of approximately 130 kDa and is expressed in various tissues with significant expression noted in the brain and muscle. The gene encoding DGKD is located on human chromosome 13 providing insights into its systemic importance.
Biological function summary
DGKD participates in regulating intracellular signaling. DGKD modulates signal transduction by altering levels of second messengers like DAG. This regulation occurs because DGKD acts as a part of lipid kinase activities impacting membrane-bound complexes involved in signal pathways. These activities can play roles in neurotransmitter release and cellular responses to external stimuli signifying their critical involvement in maintaining cellular homeostasis.
Pathways
DGKD plays a role in the phosphatidylinositol signaling system by interacting with and regulating proteins such as Protein Kinase C (PKC). This involvement means that it influences the kinase activity responsible for numerous cellular responses including cell growth apoptosis and metabolism. Additionally DGKD appears in the broader MAPK/ERK pathway indicating links with cellular proliferation and survival signals and suggesting its interconnectedness with a network of kinases and phosphatases.
DGKD abnormalities have connections with conditions like insulin resistance and neurological disorders. Studies point out its potential interaction with proteins like IRS1 in insulin signaling pathways where altered DGKD function might influence metabolic pathways leading to insulin resistance. Furthermore its significant presence in the brain suggests possible links to neurological conditions potentially through influencing synaptic signal regulation or cellular communication networks.